Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 21:30:01 04/06/2024 BST			5-day change	1st Jan Change
2.52 ^USD	+1.20%		+9.09%	+7.23%

06-03	LIXTE Biotechnology Holdings, Inc. Announces Executive Changes	CI
05-09	Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board

January 07, 2014 at 02:01 pm

Lixte Biotechnology Holdings, Inc. announced the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board. Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen.

Latest news about Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes	06-03	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Lixte Biotechnology Files Up to $50 Million Mixed Shelf	04-23	MT
Sector Update: Health Care Stocks Advance Late Afternoon	03-27	MT
Top Midday Gainers	03-27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	03-27	MT
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	03-27	CI
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	03-21	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	02-26	CI
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	01-29	CI
Top Premarket Decliners	11-28	MT
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Warrants of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Options of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Options of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Warrants of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	18/10/23	CI
Lixte Biotechnology Extends Partnership With Netherlands Cancer Institute, Oncode Institute for Cancer Therapies Investigation	16/10/23	MT
Lixte Biotechnology Names Bas van der Baan as Chief Executive	26/09/23	MT
Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes	26/09/23	CI
Lixte Biotechnology Holdings, Inc. Announces Executive Changes	26/09/23	CI

Chart Lixte Biotechnology Holdings, Inc.

Duration

Period

Chart Lixte Biotechnology Holdings, Inc.

More charts

Company Profile

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Companyâs product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LIXTE BIOTECHNOLOGY HOLDINGS, INC.	+7.23%	5.67M
MODERNA, INC.	+46.19%	55.7B
LONZA GROUP AG	+39.55%	39.91B
IQVIA HOLDINGS INC.	-6.14%	39.57B
CELLTRION, INC.	-6.65%	28.16B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	18.94B
MEDPACE HOLDINGS, INC.	+28.38%	12.17B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.12B
BIO-TECHNE CORPORATION	-0.35%	12.12B

Other Biotechnology & Medical Research